fbpx

Vision Expo East Announces Innovative New Education Content

Alexandria, VA – Numerous innovative programs have been added to the education curriculum at International Vision Expo East 2017, taking place at the Javits Center in New York, NY (Education: Mar. 30–Apr. 2; Exhibition: Mar. 31–Apr. 3). Registration is now open for the industry’s most comprehensive continuing education program, held steps away from the largest exhibit hall of eyewear and eyecare products in the Americas.

“Vision Expo East 2017 features over 300 hours of continuing education, including 20 specialty tracks,” said Mark Dunbar, OD, FAAO, Co-Chairman, Conference Advisory Board. “Attendees have access to endless program choices developed and delivered by the industry’s most prestigious lecturers, which is just one of the reasons why 99% of eyecare professionals attending say they gain valuable insights at International Vision Expo that will have a positive impact on their practice.”

The attendee-favorite Global Contact Lens Forum returns as a “meeting within a meeting”, with a new format offering direct access to thought leaders discussing the future of the contact lens practice, along with the latest advancements and critical business strategies.

The Ocular Surface Disease and Wellness Symposium will teach attendees how an ocular practice can mirror a preventative care model to better diagnose and treat patients, and the expertise needed to recognize dry eye diseases.

“Vision Expo is noted for its diversified curriculum applicable to all eyecare providers, covering the latest hot-topics,” said Ben Gaddie, OD, FAAO, Co-Chairman, Conference Advisory Board. “This year, we are excited to unveil an innovative collaboration with the biggest name in technology. As the global hub for the eyecare industry, we’re bringing attendees a high-value experience throughout all four days.”

New education programs at International Vision Expo East 2017:

  • The all-new Vision Series format allows attendees to continue learning over lunch while industry leaders address the latest clinical innovations.
  • Building on its success and high demand from Vision Expo West, Vision Expo East will host a new, expanded Scleral Lens Track including a hands-on workshop. Attendees will gain a thorough understanding of the scleral lens fitting process and advanced problem solving techniques.
  • Attendees will learn from the next generation of industry leaders at the Intrepid Talks, where members of The Intrepid Eye Society present on the advancement of optometry covering topics related to future medical therapeutics/delivery platforms, diagnostics, collaborative care models, practice development and more.
  • New Blue Light sessions present everything from the latest research findings to the basics of blue light—both indoors and outside—and how to communicate this critical information and offer the best solutions to patients.
  • The new Practice Owner & Manager Essentials program will focus on the business side of optometry for doctors and key decision makers, including strategies doctors need to grow business.
  • The newly created, retail-focused Manager’s ‘To-Do-List’ mini-track features actionable takeaways attendees can immediately implement.

Additionally, Vision Expo has partnered with Google and Marketing4ECPs to share techniques to optimize technology to grow business. More details will be announced in January.

 

Featured Posts

Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read More
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read More
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read More
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more